AU2006210973A1 - Nucleic acid silencing of Huntington's Disease gene - Google Patents

Nucleic acid silencing of Huntington's Disease gene Download PDF

Info

Publication number: AU2006210973A1
Authority: AU; Australia
Prior art keywords: seq; sirna; strand; rna; expression
Prior art date: 2005-01-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2006210973A

Other languages

English (en)

Inventor

Beverly L. Davidson

Scott Harper

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Iowa Research Foundation UIRF

Original Assignee

University of Iowa Research Foundation UIRF

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-31

Filing date

2006-01-31

Publication date

2006-08-10

2005-01-31 Priority claimed from US11/048,627 external-priority patent/US20050255086A1/en

2006-01-31 Application filed by University of Iowa Research Foundation UIRF filed Critical University of Iowa Research Foundation UIRF

2006-08-10 Publication of AU2006210973A1 publication Critical patent/AU2006210973A1/en

Status Abandoned legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims description 383
150000007523 nucleic acids Chemical class 0.000 title claims description 200
102000039446 nucleic acids Human genes 0.000 title claims description 132
108020004707 nucleic acids Proteins 0.000 title claims description 132
208000023105 Huntington disease Diseases 0.000 title claims description 73
230000030279 gene silencing Effects 0.000 title claims description 64
108020004459 Small interfering RNA Proteins 0.000 claims description 446
239000004055 small Interfering RNA Substances 0.000 claims description 408
210000004027 cell Anatomy 0.000 claims description 337
230000014509 gene expression Effects 0.000 claims description 329
108700028369 Alleles Proteins 0.000 claims description 171
239000002773 nucleotide Substances 0.000 claims description 169
125000003729 nucleotide group Chemical group 0.000 claims description 168
238000000034 method Methods 0.000 claims description 146
102000004169 proteins and genes Human genes 0.000 claims description 134
239000013598 vector Substances 0.000 claims description 121
230000006870 function Effects 0.000 claims description 79
230000000295 complement effect Effects 0.000 claims description 67
239000013603 viral vector Substances 0.000 claims description 48
238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 47
230000009368 gene silencing by RNA Effects 0.000 claims description 47
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 46
210000004962 mammalian cell Anatomy 0.000 claims description 44
230000003612 virological effect Effects 0.000 claims description 35
101710177611 DNA polymerase II large subunit Proteins 0.000 claims description 33
101710184669 DNA polymerase II small subunit Proteins 0.000 claims description 33
241000124008 Mammalia Species 0.000 claims description 27
238000012226 gene silencing method Methods 0.000 claims description 27
239000013607 AAV vector Substances 0.000 claims description 25
241001529936 Murinae Species 0.000 claims description 13
239000003550 marker Substances 0.000 claims description 13
230000004962 physiological condition Effects 0.000 claims description 13
241000991587 Enterovirus C Species 0.000 claims description 8
229920002477 rna polymer Polymers 0.000 description 161
102000053602 DNA Human genes 0.000 description 123
108020004414 DNA Proteins 0.000 description 122
235000018102 proteins Nutrition 0.000 description 116
108091028043 Nucleic acid sequence Proteins 0.000 description 112
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 98
201000010099 disease Diseases 0.000 description 91
102000007371 Ataxin-3 Human genes 0.000 description 67
108010032947 Ataxin-3 Proteins 0.000 description 66
239000013612 plasmid Substances 0.000 description 57
241000701161 unidentified adenovirus Species 0.000 description 51
108090000765 processed proteins & peptides Proteins 0.000 description 50
241000700605 Viruses Species 0.000 description 47
230000035897 transcription Effects 0.000 description 45
238000013518 transcription Methods 0.000 description 45
108020004999 messenger RNA Proteins 0.000 description 44
108010040003 polyglutamine Proteins 0.000 description 41
239000013604 expression vector Substances 0.000 description 39
230000000694 effects Effects 0.000 description 38
102000004196 processed proteins & peptides Human genes 0.000 description 38
230000035772 mutation Effects 0.000 description 37
238000001890 transfection Methods 0.000 description 37
238000001727 in vivo Methods 0.000 description 36
229920001184 polypeptide Polymers 0.000 description 36
239000005090 green fluorescent protein Substances 0.000 description 34
230000001105 regulatory effect Effects 0.000 description 34
208000015122 neurodegenerative disease Diseases 0.000 description 33
108091026890 Coding region Proteins 0.000 description 32
239000012634 fragment Substances 0.000 description 32
101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 31
102100021244 Integral membrane protein GPR180 Human genes 0.000 description 31
230000001404 mediated effect Effects 0.000 description 30
238000001262 western blot Methods 0.000 description 30
238000000338 in vitro Methods 0.000 description 29
238000002560 therapeutic procedure Methods 0.000 description 27
230000004770 neurodegeneration Effects 0.000 description 26
208000002569 Machado-Joseph Disease Diseases 0.000 description 25
108091034117 Oligonucleotide Proteins 0.000 description 25
238000009396 hybridization Methods 0.000 description 25
238000006467 substitution reaction Methods 0.000 description 25
102000013498 tau Proteins Human genes 0.000 description 25
108010026424 tau Proteins Proteins 0.000 description 25
230000001225 therapeutic effect Effects 0.000 description 25
208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 24
208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 24
238000002474 experimental method Methods 0.000 description 24
239000000203 mixture Substances 0.000 description 24
229920000155 polyglutamine Polymers 0.000 description 24
230000009467 reduction Effects 0.000 description 24
230000014616 translation Effects 0.000 description 24
239000000463 material Substances 0.000 description 23
230000008488 polyadenylation Effects 0.000 description 23
102000040650 (ribonucleotides)n+m Human genes 0.000 description 22
241000701022 Cytomegalovirus Species 0.000 description 22
235000001014 amino acid Nutrition 0.000 description 22
230000001629 suppression Effects 0.000 description 22
238000013519 translation Methods 0.000 description 22
230000002829 reductive effect Effects 0.000 description 21
210000001519 tissue Anatomy 0.000 description 21
210000002845 virion Anatomy 0.000 description 21
108020004511 Recombinant DNA Proteins 0.000 description 20
108091027967 Small hairpin RNA Proteins 0.000 description 20
208000015181 infectious disease Diseases 0.000 description 20
208000012902 Nervous system disease Diseases 0.000 description 19
239000003814 drug Substances 0.000 description 19
230000010076 replication Effects 0.000 description 19
108020004705 Codon Proteins 0.000 description 18
229940024606 amino acid Drugs 0.000 description 18
150000001413 amino acids Chemical class 0.000 description 18
241000699670 Mus sp. Species 0.000 description 17
108700026244 Open Reading Frames Proteins 0.000 description 17
210000003169 central nervous system Anatomy 0.000 description 17
230000000875 corresponding effect Effects 0.000 description 17
238000012217 deletion Methods 0.000 description 17
230000037430 deletion Effects 0.000 description 17
238000004519 manufacturing process Methods 0.000 description 17
229940124597 therapeutic agent Drugs 0.000 description 17
101000662686 Homo sapiens Torsin-1A Proteins 0.000 description 16
102100037454 Torsin-1A Human genes 0.000 description 16
210000004556 brain Anatomy 0.000 description 16
101150113725 hd gene Proteins 0.000 description 16
238000004806 packaging method and process Methods 0.000 description 16
238000003752 polymerase chain reaction Methods 0.000 description 16
230000008569 process Effects 0.000 description 16
238000012360 testing method Methods 0.000 description 16
230000001413 cellular effect Effects 0.000 description 15
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
201000011240 Frontotemporal dementia Diseases 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
125000003275 alpha amino acid group Chemical group 0.000 description 14
239000002299 complementary DNA Substances 0.000 description 14
239000003623 enhancer Substances 0.000 description 14
241001430294 unidentified retrovirus Species 0.000 description 14
241000702421 Dependoparvovirus Species 0.000 description 13
208000014094 Dystonic disease Diseases 0.000 description 13
210000002569 neuron Anatomy 0.000 description 13
239000002245 particle Substances 0.000 description 13
239000000243 solution Substances 0.000 description 13
206010003694 Atrophy Diseases 0.000 description 12
108700019146 Transgenes Proteins 0.000 description 12
238000007792 addition Methods 0.000 description 12
230000037444 atrophy Effects 0.000 description 12
230000027455 binding Effects 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 12
239000013613 expression plasmid Substances 0.000 description 12
230000000977 initiatory effect Effects 0.000 description 12
239000007924 injection Substances 0.000 description 12
238000002347 injection Methods 0.000 description 12
230000010354 integration Effects 0.000 description 12
230000009261 transgenic effect Effects 0.000 description 12
238000011144 upstream manufacturing Methods 0.000 description 12
108010021466 Mutant Proteins Proteins 0.000 description 11
102000008300 Mutant Proteins Human genes 0.000 description 11
238000000636 Northern blotting Methods 0.000 description 11
241000700584 Simplexvirus Species 0.000 description 11
208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
208000010118 dystonia Diseases 0.000 description 11
238000011065 in-situ storage Methods 0.000 description 11
238000003780 insertion Methods 0.000 description 11
230000037431 insertion Effects 0.000 description 11
238000011068 loading method Methods 0.000 description 11
230000007246 mechanism Effects 0.000 description 11
102000040430 polynucleotide Human genes 0.000 description 11
108091033319 polynucleotide Proteins 0.000 description 11
239000002157 polynucleotide Substances 0.000 description 11
239000002924 silencing RNA Substances 0.000 description 11
102100021321 Ataxin-3 Human genes 0.000 description 10
108090000565 Capsid Proteins Proteins 0.000 description 10
102100023321 Ceruloplasmin Human genes 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 10
241000714474 Rous sarcoma virus Species 0.000 description 10
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
230000000692 anti-sense effect Effects 0.000 description 10
210000000349 chromosome Anatomy 0.000 description 10
238000010790 dilution Methods 0.000 description 10
239000012895 dilution Substances 0.000 description 10
238000003197 gene knockdown Methods 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
230000002452 interceptive effect Effects 0.000 description 10
239000008194 pharmaceutical composition Substances 0.000 description 10
238000010361 transduction Methods 0.000 description 10
230000026683 transduction Effects 0.000 description 10
238000012546 transfer Methods 0.000 description 10
101150074725 Atxn3 gene Proteins 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 9
238000001415 gene therapy Methods 0.000 description 9
230000002068 genetic effect Effects 0.000 description 9
230000001939 inductive effect Effects 0.000 description 9
230000001603 reducing effect Effects 0.000 description 9
239000000523 sample Substances 0.000 description 9
241000580270 Adeno-associated virus - 4 Species 0.000 description 8
102100032187 Androgen receptor Human genes 0.000 description 8
201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 8
241000196324 Embryophyta Species 0.000 description 8
108010060309 Glucuronidase Proteins 0.000 description 8
101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 8
108010076504 Protein Sorting Signals Proteins 0.000 description 8
208000009415 Spinocerebellar Ataxias Diseases 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
230000008859 change Effects 0.000 description 8
238000003776 cleavage reaction Methods 0.000 description 8
238000011161 development Methods 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
108020001507 fusion proteins Proteins 0.000 description 8
102000037865 fusion proteins Human genes 0.000 description 8
230000007017 scission Effects 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
241000894007 species Species 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
230000008685 targeting Effects 0.000 description 8
230000004543 DNA replication Effects 0.000 description 7
208000025966 Neurological disease Diseases 0.000 description 7
102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 7
108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 7
108700008625 Reporter Genes Proteins 0.000 description 7
230000035508 accumulation Effects 0.000 description 7
238000009825 accumulation Methods 0.000 description 7
230000004075 alteration Effects 0.000 description 7
238000013459 approach Methods 0.000 description 7
238000003556 assay Methods 0.000 description 7
230000008901 benefit Effects 0.000 description 7
210000000234 capsid Anatomy 0.000 description 7
230000007423 decrease Effects 0.000 description 7
238000013461 design Methods 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
230000001697 htt accumulation Effects 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
238000012552 review Methods 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
239000000126 substance Substances 0.000 description 7
230000002588 toxic effect Effects 0.000 description 7
230000005026 transcription initiation Effects 0.000 description 7
101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 6
102000053187 Glucuronidase Human genes 0.000 description 6
101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 6
108091081024 Start codon Proteins 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
239000000499 gel Substances 0.000 description 6
238000012744 immunostaining Methods 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
238000002844 melting Methods 0.000 description 6
230000008018 melting Effects 0.000 description 6
108091070501 miRNA Proteins 0.000 description 6
239000002679 microRNA Substances 0.000 description 6
210000003061 neural cell Anatomy 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
230000000069 prophylactic effect Effects 0.000 description 6
231100000563 toxic property Toxicity 0.000 description 6
230000002103 transcriptional effect Effects 0.000 description 6
230000009466 transformation Effects 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 5
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
208000028782 Hereditary disease Diseases 0.000 description 5
108091092195 Intron Proteins 0.000 description 5
108700009124 Transcription Initiation Site Proteins 0.000 description 5
102000004243 Tubulin Human genes 0.000 description 5
108090000704 Tubulin Proteins 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
230000001186 cumulative effect Effects 0.000 description 5
230000002950 deficient Effects 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
229960003722 doxycycline Drugs 0.000 description 5
238000009472 formulation Methods 0.000 description 5
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
238000001802 infusion Methods 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
238000007918 intramuscular administration Methods 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
239000003446 ligand Substances 0.000 description 5
239000006166 lysate Substances 0.000 description 5
239000013642 negative control Substances 0.000 description 5
210000001577 neostriatum Anatomy 0.000 description 5
230000001537 neural effect Effects 0.000 description 5
230000032361 posttranscriptional gene silencing Effects 0.000 description 5
238000012545 processing Methods 0.000 description 5
238000011002 quantification Methods 0.000 description 5
230000004044 response Effects 0.000 description 5
230000001177 retroviral effect Effects 0.000 description 5
238000012216 screening Methods 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
230000005030 transcription termination Effects 0.000 description 5
241001529453 unidentified herpesvirus Species 0.000 description 5
102000007469 Actins Human genes 0.000 description 4
108010085238 Actins Proteins 0.000 description 4
102000014461 Ataxins Human genes 0.000 description 4
108010078286 Ataxins Proteins 0.000 description 4
206010008025 Cerebellar ataxia Diseases 0.000 description 4
108050000299 Chemokine receptor Proteins 0.000 description 4
102000009410 Chemokine receptor Human genes 0.000 description 4
102000019034 Chemokines Human genes 0.000 description 4
108010012236 Chemokines Proteins 0.000 description 4
108091029865 Exogenous DNA Proteins 0.000 description 4
241000713666 Lentivirus Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
108060004795 Methyltransferase Proteins 0.000 description 4
241000288906 Primates Species 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
201000003622 Spinocerebellar ataxia type 2 Diseases 0.000 description 4
239000004098 Tetracycline Substances 0.000 description 4
108020004566 Transfer RNA Proteins 0.000 description 4
201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 4
108010005774 beta-Galactosidase Proteins 0.000 description 4
210000004958 brain cell Anatomy 0.000 description 4
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
230000003915 cell function Effects 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000000975 co-precipitation Methods 0.000 description 4
238000010276 construction Methods 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
210000004748 cultured cell Anatomy 0.000 description 4
230000007547 defect Effects 0.000 description 4
230000002939 deleterious effect Effects 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
230000003292 diminished effect Effects 0.000 description 4
230000004064 dysfunction Effects 0.000 description 4
238000004520 electroporation Methods 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
238000010166 immunofluorescence Methods 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
230000002458 infectious effect Effects 0.000 description 4
238000002955 isolation Methods 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
230000005012 migration Effects 0.000 description 4
238000013508 migration Methods 0.000 description 4
238000002703 mutagenesis Methods 0.000 description 4
231100000350 mutagenesis Toxicity 0.000 description 4
238000005457 optimization Methods 0.000 description 4
230000007170 pathology Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
230000001124 posttranscriptional effect Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
229960002180 tetracycline Drugs 0.000 description 4
229930101283 tetracycline Natural products 0.000 description 4
235000019364 tetracycline Nutrition 0.000 description 4
150000003522 tetracyclines Chemical class 0.000 description 4
230000010474 transient expression Effects 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
108020005544 Antisense RNA Proteins 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
108091032955 Bacterial small RNA Proteins 0.000 description 3
206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 3
108010077544 Chromatin Proteins 0.000 description 3
102000012410 DNA Ligases Human genes 0.000 description 3
108010061982 DNA Ligases Proteins 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010019468 Hemiplegia Diseases 0.000 description 3
108091027305 Heteroduplex Proteins 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
101001030705 Homo sapiens Huntingtin Proteins 0.000 description 3
101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 3
241001135569 Human adenovirus 5 Species 0.000 description 3
208000027747 Kennedy disease Diseases 0.000 description 3
208000024556 Mendelian disease Diseases 0.000 description 3
108090000157 Metallothionein Proteins 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
208000018737 Parkinson disease Diseases 0.000 description 3
241000125945 Protoparvovirus Species 0.000 description 3
102000017143 RNA Polymerase I Human genes 0.000 description 3
108010013845 RNA Polymerase I Proteins 0.000 description 3
102000009572 RNA Polymerase II Human genes 0.000 description 3
108010009460 RNA Polymerase II Proteins 0.000 description 3
102000014450 RNA Polymerase III Human genes 0.000 description 3
108010078067 RNA Polymerase III Proteins 0.000 description 3
108020004682 Single-Stranded DNA Proteins 0.000 description 3
108700026226 TATA Box Proteins 0.000 description 3
108020005038 Terminator Codon Proteins 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
210000005013 brain tissue Anatomy 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
210000003483 chromatin Anatomy 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
238000010668 complexation reaction Methods 0.000 description 3
239000005547 deoxyribonucleotide Substances 0.000 description 3
-1 deoxyribonucleotide triphosphates Chemical class 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
235000013922 glutamic acid Nutrition 0.000 description 3
239000004220 glutamic acid Substances 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
102000057063 human MAPT Human genes 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
201000010901 lateral sclerosis Diseases 0.000 description 3
239000002502 liposome Substances 0.000 description 3
238000000520 microinjection Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
208000005264 motor neuron disease Diseases 0.000 description 3
229940126619 mouse monoclonal antibody Drugs 0.000 description 3
201000006417 multiple sclerosis Diseases 0.000 description 3
210000000653 nervous system Anatomy 0.000 description 3
108091027963 non-coding RNA Proteins 0.000 description 3
102000042567 non-coding RNA Human genes 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
210000001428 peripheral nervous system Anatomy 0.000 description 3
102000054765 polymorphisms of proteins Human genes 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
101150066583 rep gene Proteins 0.000 description 3
230000003362 replicative effect Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
201000008417 spastic hemiplegia Diseases 0.000 description 3
208000002320 spinal muscular atrophy Diseases 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000002463 transducing effect Effects 0.000 description 3
238000011830 transgenic mouse model Methods 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
108700026220 vif Genes Proteins 0.000 description 3
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
241000710929 Alphavirus Species 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
102000003844 DNA helicases Human genes 0.000 description 2
108090000133 DNA helicases Proteins 0.000 description 2
241000450599 DNA viruses Species 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
241000713800 Feline immunodeficiency virus Species 0.000 description 2
102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
108700005000 Glial Fibrillary Acidic Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
101710154606 Hemagglutinin Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000895100 Homo sapiens Ataxin-3 Proteins 0.000 description 2
241000701027 Human herpesvirus 6 Species 0.000 description 2
241000243251 Hydra Species 0.000 description 2
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
208000026350 Inborn Genetic disease Diseases 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
101710128836 Large T antigen Proteins 0.000 description 2
108091027974 Mature messenger RNA Proteins 0.000 description 2
241001599018 Melanogaster Species 0.000 description 2
102000003792 Metallothionein Human genes 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
241000701945 Parvoviridae Species 0.000 description 2
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
208000032319 Primary lateral sclerosis Diseases 0.000 description 2
101710176177 Protein A56 Proteins 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
108010022394 Threonine synthase Proteins 0.000 description 2
241000397921 Turbellaria Species 0.000 description 2
206010046298 Upper motor neurone lesion Diseases 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
210000004227 basal ganglia Anatomy 0.000 description 2
230000006736 behavioral deficit Effects 0.000 description 2
102000005936 beta-Galactosidase Human genes 0.000 description 2
230000002146 bilateral effect Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
238000010170 biological method Methods 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
239000012707 chemical precursor Substances 0.000 description 2
238000012761 co-transfection Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
238000001514 detection method Methods 0.000 description 2
102000004419 dihydrofolate reductase Human genes 0.000 description 2
241001493065 dsRNA viruses Species 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000001973 epigenetic effect Effects 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
201000002904 focal dystonia Diseases 0.000 description 2
230000004927 fusion Effects 0.000 description 2
201000002886 generalized dystonia Diseases 0.000 description 2
208000016361 genetic disease Diseases 0.000 description 2
150000002307 glutamic acids Chemical group 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229940029575 guanosine Drugs 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
239000000185 hemagglutinin Substances 0.000 description 2
102000056336 human ATXN3 Human genes 0.000 description 2
102000054185 human HTT Human genes 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
238000010191 image analysis Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000002743 insertional mutagenesis Methods 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000005228 liver tissue Anatomy 0.000 description 2
230000004807 localization Effects 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
230000037230 mobility Effects 0.000 description 2
239000000178 monomer Substances 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
210000002682 neurofibrillary tangle Anatomy 0.000 description 2
230000006764 neuronal dysfunction Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000003950 pathogenic mechanism Effects 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
108010079892 phosphoglycerol kinase Proteins 0.000 description 2
238000000053 physical method Methods 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000004845 protein aggregation Effects 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
108020004418 ribosomal RNA Proteins 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
238000003151 transfection method Methods 0.000 description 2
230000009752 translational inhibition Effects 0.000 description 2
230000010415 tropism Effects 0.000 description 2
102100027831 14-3-3 protein theta Human genes 0.000 description 1
VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
101150055869 25 gene Proteins 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
108020005075 5S Ribosomal RNA Proteins 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
241001655883 Adeno-associated virus - 1 Species 0.000 description 1
241000972680 Adeno-associated virus - 6 Species 0.000 description 1
101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
102100034452 Alternative prion protein Human genes 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
101710095339 Apolipoprotein E Proteins 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
102000007372 Ataxin-1 Human genes 0.000 description 1
108010032963 Ataxin-1 Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
101150044789 Cap gene Proteins 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
108091062157 Cis-regulatory element Proteins 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
241000724252 Cucumber mosaic virus Species 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
238000000116 DAPI staining Methods 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000702224 Enterobacteria phage M13 Species 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
101100164984 Homo sapiens ATXN3 gene Proteins 0.000 description 1
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
102000016252 Huntingtin Human genes 0.000 description 1
108050004784 Huntingtin Proteins 0.000 description 1
102100038562 Huntingtin Human genes 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
208000031942 Late Onset disease Diseases 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
108020004485 Nonsense Codon Proteins 0.000 description 1
108010077850 Nuclear Localization Signals Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000254064 Photinus pyralis Species 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
101710150114 Protein rep Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
108020005115 Pyruvate Kinase Proteins 0.000 description 1
102000013009 Pyruvate Kinase Human genes 0.000 description 1
108090000944 RNA Helicases Proteins 0.000 description 1
102000004409 RNA Helicases Human genes 0.000 description 1
102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
230000007022 RNA scission Effects 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
101710152114 Replication protein Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
201000003620 Spinocerebellar ataxia type 6 Diseases 0.000 description 1
101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
241001365914 Taira Species 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
108091034131 VA RNA Proteins 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
230000007488 abnormal function Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000006154 adenylylation Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
239000002787 antisense oligonuctleotide Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
101150038410 atx-3 gene Proteins 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
238000012219 cassette mutagenesis Methods 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000015861 cell surface binding Effects 0.000 description 1
210000004671 cell-free system Anatomy 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000000877 corpus callosum Anatomy 0.000 description 1
238000012937 correction Methods 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
230000005860 defense response to virus Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
208000016570 early-onset generalized limb-onset dystonia Diseases 0.000 description 1
UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
238000012632 fluorescent imaging Methods 0.000 description 1
238000007421 fluorometric assay Methods 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000005021 gait Effects 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
230000030414 genetic transfer Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000004565 granule cell Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000044890 human EPO Human genes 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
229940097277 hygromycin b Drugs 0.000 description 1
238000005286 illumination Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
208000016245 inborn errors of metabolism Diseases 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
208000015978 inherited metabolic disease Diseases 0.000 description 1
208000030309 inherited neurodegenerative disease Diseases 0.000 description 1
239000003999 initiator Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
230000003447 ipsilateral effect Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
210000003140 lateral ventricle Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
150000002690 malonic acid derivatives Chemical class 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000002052 molecular layer Substances 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
230000037434 nonsense mutation Effects 0.000 description 1
231100001221 nontumorigenic Toxicity 0.000 description 1
108010058731 nopaline synthase Proteins 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
210000003245 peritoneal mesothelial cell Anatomy 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000000379 polymerizing effect Effects 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000012743 protein tagging Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
239000013608 rAAV vector Substances 0.000 description 1
239000013645 rAAV1 vector Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
108010054624 red fluorescent protein Proteins 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
230000000754 repressing effect Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
238000010825 rotarod performance test Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 1
108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
230000006807 siRNA silencing Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 1
201000003632 spinocerebellar ataxia type 7 Diseases 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
229940026804 topical antibiotic tetracycline and derivative Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000005758 transcription activity Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
239000010937 tungsten Substances 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2006210973A 2005-01-31 2006-01-31 Nucleic acid silencing of Huntington's Disease gene Abandoned AU2006210973A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11/048,627 US20050255086A1 (en)	2002-08-05	2005-01-31	Nucleic acid silencing of Huntington's Disease gene
US11/048,627		2005-01-31
PCT/US2006/003298 WO2006083800A2 (fr)	2005-01-31	2006-01-31	Silençage nucleique de gene de maladie d'huntington

Publications (1)

Publication Number	Publication Date
AU2006210973A1 true AU2006210973A1 (en)	2006-08-10

Family

ID=36777811

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2006210973A Abandoned AU2006210973A1 (en)	2005-01-31	2006-01-31	Nucleic acid silencing of Huntington's Disease gene

Country Status (4)

Country	Link
EP (1)	EP1844148A2 (fr)
AU (1)	AU2006210973A1 (fr)
CA (1)	CA2596588C (fr)
WO (1)	WO2006083800A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002166817A (ja)	1999-10-01	2002-06-11	Daicel Chem Ind Ltd	ハイブリッドインフレータ
US20040241854A1 (en)	2002-08-05	2004-12-02	Davidson Beverly L.	siRNA-mediated gene silencing
US20050042646A1 (en)	2002-08-05	2005-02-24	Davidson Beverly L.	RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20080274989A1 (en)	2002-08-05	2008-11-06	University Of Iowa Research Foundation	Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20080039415A1 (en) *	2006-08-11	2008-02-14	Gregory Robert Stewart	Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
WO2008018795A1 (fr)	2006-08-11	2008-02-14	Prosensa Technologies B.V.	Procédés et moyens de traitement de troubles génétiques associés à l'instabilité des répétitions de l'ADN
CA2688514A1 (fr)	2007-04-26	2008-11-06	University Of Iowa Research Foundation	Suppression de l'interference par l'arn des maladies neurodegeneratives et ses methodes d'utilisation
AU2008260103B2 (en)	2007-05-31	2014-04-03	University Of Iowa Research Foundation	Reduction of off-target RNA interference toxicity
DK2167136T3 (en)	2007-07-12	2016-07-25	Biomarin Tech Bv	Molecules for targeting compounds at different selected organs or tissues
EP2167135A2 (fr)	2007-07-12	2010-03-31	Prosensa Technologies B.V.	Molécules pour cibler les composants vers plusieurs organes sélectionnés, tissus ou cellules de tumeurs
USRE48468E1 (en)	2007-10-26	2021-03-16	Biomarin Technologies B.V.	Means and methods for counteracting muscle disorders
NZ584793A (en)	2007-10-26	2012-05-25	Academisch Ziekenhuis Leiden	Means and methods for counteracting muscle disorders
NZ587178A (en)	2008-02-08	2011-11-25	Prosensa Holding Bv	Methods and means for treating dna repeat instability associated genetic disorders
EP2119783A1 (fr)	2008-05-14	2009-11-18	Prosensa Technologies B.V.	Procédé pour l'omission efficace de l'exon (44) dans la dystrophie musculaire de Duchenne et moyens connexes
JP2012524540A (ja)	2009-04-24	2012-10-18	プロセンサテクノロジーズビー．ブイ．	Ｄｍｄを処置するためのイノシンを含むオリゴヌクレオチド
WO2012109667A1 (fr)	2011-02-12	2012-08-16	University Of Iowa Research Foundation	Composés thérapeutiques
EP2806900B1 (fr)	2012-01-27	2021-12-15	BioMarin Technologies B.V.	Oligonucléotides de modulation arn ayant des caractéristiques améliorées pour le traitement de la dystrophie musculaire de duchenne et becker
SI2841578T1 (sl)	2012-04-23	2017-12-29	Biomarin Technologies B.V.	Rna modulirajoči oligonukleotidi z izboljšanimi karakteristikami za zdravljenje nevromuskularnih motenj
JP6628285B2 (ja)	2013-03-14	2020-01-08	ユニバーシティオブフロリダリサーチファンデーションインコーポレーティッド	Ａｌｓ関連ジアミノ酸リピート含有タンパク質
CA2949437C (fr)	2014-05-20	2023-08-15	University Of Iowa Research Foundation	Composes therapeutiques pour la maladie de huntington
US10509045B2 (en)	2015-05-29	2019-12-17	University Of Florida Research Foundation, Incorporated	Methods for diagnosing Huntington's disease
US10940161B2 (en)	2016-04-04	2021-03-09	University Of Florida Research Foundation, Incorporated	Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
JP7220080B2 (ja)	2016-05-18	2023-02-09	ボイジャーセラピューティクスインコーポレイテッド	ハンチントン病治療組成物及び方法
CA3060250A1 (fr)	2017-04-17	2018-10-25	University Of Florida Research Foundation, Incorporated	Regulation de la traduction de la proteine ran par les voies pkr et eif2a-p
KR20200056428A (ko) *	2017-09-22	2020-05-22	젠자임 코포레이션	변이체 RNAi
CA3076214A1 (fr)	2017-09-26	2019-04-04	University Of Florida Research Foundation, Incorporated	Utilisation de metformine et d'analogues de celle-ci pour reduire les taux de proteine ran lors d'un traitement de troubles neurologiques
KR20200075865A (ko) *	2017-10-23	2020-06-26	프리베일 테라퓨틱스, 인크.	신경변성 질환에 대한 유전자 요법
CN112980837B (zh) *	2019-12-13	2023-07-04	深圳艾码生物科技有限公司	一种抑制HTT基因表达的siRNA及其前体和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050106731A1 (en) *	2002-08-05	2005-05-19	Davidson Beverly L.	siRNA-mediated gene silencing with viral vectors
US20050255086A1 (en) *	2002-08-05	2005-11-17	Davidson Beverly L	Nucleic acid silencing of Huntington's Disease gene
US20050042646A1 (en) *	2002-08-05	2005-02-24	Davidson Beverly L.	RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US7605249B2 (en) *	2002-11-26	2009-10-20	Medtronic, Inc.	Treatment of neurodegenerative disease through intracranial delivery of siRNA
WO2005105995A2 (fr) *	2004-04-14	2005-11-10	Sirna Therapeutics, Inc.	Traitement de maladies a expansion de sequence repetee de polyglutamine (polyq) a mediation d'arn interferent mettant en oeuvre un acide nucleique court interferent (sina)

2006
- 2006-01-31 CA CA2596588A patent/CA2596588C/fr active Active
- 2006-01-31 EP EP06734091A patent/EP1844148A2/fr not_active Withdrawn
- 2006-01-31 WO PCT/US2006/003298 patent/WO2006083800A2/fr active Application Filing
- 2006-01-31 AU AU2006210973A patent/AU2006210973A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1844148A2 (fr)	2007-10-17
CA2596588A1 (fr)	2006-08-10
CA2596588C (fr)	2017-06-27
WO2006083800A2 (fr)	2006-08-10
WO2006083800A3 (fr)	2007-03-01

Legal Events

Date	Code	Title	Description
2012-05-17	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted

Publication	Publication Date	Title
US10072264B2 (en)	2018-09-11	RNA interference suppression of neurodegenerative diseases and methods of use
CA2596588C (fr)	2017-06-27	Silencage nucleique de gene de maladie d'huntington
US20050255086A1 (en)	2005-11-17	Nucleic acid silencing of Huntington's Disease gene
US8524879B2 (en)	2013-09-03	RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US8779116B2 (en)	2014-07-15	SiRNA-mediated gene silencing
AU2009202278B8 (en)	2012-11-29	Allele-specific sirna-mediated gene silencing
US9169483B2 (en)	2015-10-27	RNA interference suppression of neurodegenerative diseases and methods of use thereof
US9388410B2 (en)	2016-07-12	Alternative export pathways for vector expressed RNA interference
US20080176812A1 (en)	2008-07-24	Allele-specific silencing of disease genes
US20090105169A1 (en)	2009-04-23	Allele-specific silencing of disease genes
AU2005200827B2 (en)	2005-07-14	Allele-specific siRNA-mediated gene silencing
EP1581635A2 (fr)	2005-10-05	Mise au silence de genes a mediation par sirna